Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of E6007 in Healthy Japanese Males
NCT02268838Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2014
- Primary completion
- Jul 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of milategrast in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability of E6007 as a measure of Adverse events, Plasma E6007 concentration over time period - Cmax up to 15 days and 8 more. Started Oct 2014; status: completed.
02
Drugs
milategrast
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02268838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268838.